Search | Clinical Trials Finder

Conditions: Hepatitis C
Interventions: telaprevir, ribavirin, peginterferon alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: La Jolla, California • Long Beach, California • Sacramento, California + 13 more

Conditions: Hepatitis C, Human Immunodeficiency Virus
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more

Conditions: Hepatitis C, Chronic
Interventions: Ribavirin, Peginterferon alfa-2a; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 58
States / cities: Scottsdale, Arizona • Tucson, Arizona • Anaheim, California + 46 more

Conditions: Chronic Hepatitis C Infection
Interventions: GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more

Conditions: Treatment of Hepatitis C
Interventions: Ledipasvir/Sofosbuvir FDC; Drug
Lead sponsor: Peter J. Ruane, M.D., Inc.; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatitis C, Chronic
Interventions: BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV), Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more

Conditions: Hepatitis C
Interventions: 200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C
Interventions: Sofosbuvir, Placebo, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more

Conditions: Chronic Hepatitis C
Interventions: SCV-07; Drug
Lead sponsor: SciClone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Anaheim, California • Louisville, Kentucky • Cincinnati, Ohio + 1 more

Conditions: Chronic Hepatitis C Infection
Interventions: ABT-267, ABT-450, ABT-333, Ritonavir, Ribavirin; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Bakersfield, California • Orlando, Florida • Annapolis, Maryland + 1 more

Conditions: Hepatitis C, Chronic, HIV CDC Category A1
Interventions: Sofosbuvir + Simeprevir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Hepatitis C
Interventions: Daclatasvir, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Anaheim, California • Orlando, Florida • Baltimore, Maryland + 4 more

Conditions: Chronic Hepatitis C
Interventions: Pioglitazone, Placebo Oral Tablet; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hepatitis C
Interventions: PF-00868554, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 9
States / cities: La Jolla, California • San Francisco, California • Orlando, Florida + 5 more

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF, VDV, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C
Interventions: BI 201335, PegIFN/RBV; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 20
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 16 more

Conditions: Chronic Hepatitis C
Interventions: BMS-650032, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Anaheim, California • Orlando, Florida • Baltimore, Maryland + 1 more

Conditions: Patient Adherence, Chronic Hepatitis C, Alcohol-related Disorders
Interventions: VBMI; Behavioral
Lead sponsor: G.V. (Sonny) Montgomery VA Medical Center; Federal
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Hepatitis C, Chronic
Interventions: RO5024048, Ribavirin [Copegus], peginterferon alfa-2a [Pegasys]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: La Jolla, California • Bradenton, Florida • Atlanta, Georgia + 14 more

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 53
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more

Conditions: Chronic Hepatitis C, Genotype 1
Interventions: Educational Intervention, Patient education and management skills training; Procedure · Other
Lead sponsor: Chronic Liver Disease Foundation; Other
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 43
States / cities: Beverly Hills, California • Calabasas, California • Santa Monica, California + 34 more

Conditions: Chronic Hepatitis C Virus
Interventions: Velpatasvir, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Costa Mesa, California • DeLand, Florida • Orlando, Florida + 6 more

Conditions: Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
Interventions: ABT-450, ABT-333, ABT-267, Ribavirin, Ritonavir; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 60
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 52 more

Search by objective public record fields.

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

Pioglitazone in Hepatitis C

A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection

Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients